A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
NRG Oncology
M.D. Anderson Cancer Center
Thomas Jefferson University
Mayo Clinic
Stanford University
Fred Hutchinson Cancer Center
Mayo Clinic
Jonsson Comprehensive Cancer Center
University of Washington
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
University of Michigan Rogel Cancer Center
Emory University
Mayo Clinic
Institut Curie
Mayo Clinic
Mayo Clinic
Mayo Clinic
NRG Oncology
Mayo Clinic
Uppsala University
Vanderbilt-Ingram Cancer Center
University of Southern California
University of Kansas Medical Center
Alliance for Clinical Trials in Oncology
British Columbia Cancer Agency
Memorial Sloan Kettering Cancer Center